伤口愈合级联相关因素中黄芪甲苷的调节机制及载体现况

Research Progress on the Regulatory Mechanisms and Carriers of Astragaloside on Wound Healing Cascade Related Factors

目的:综述伤口愈合级联相关因素中黄芪甲苷(AS-IV)的调节机制及载体的最新进展,为AS-IV干预“伤口”的再度开发和临床应用提供参考和价值依据。方法:以“黄芪甲苷”“Astragaloside IV”“伤口”“Wound”“创面”“Wound surface”为检索词,通过对中国知网、维普、万方和PubMed数据库进行逐一筛选。结果:在去除AS-IV与对伤口愈合级联的相关因素中的调节机制及载体关联性较低的文献后,最终筛选出43篇目标文献。结论:文献分析表明,在伤口愈合级联相关因素中,AS-IV相关的机制调节主要集中在保护血管,控制炎症,调节胶原的合成与转换,促进成纤维细胞和上皮细胞的增殖、迁移和分化,保护神经等方面,相关载体的研发和应用主要集中在水凝胶、纤维类和生物材料等方面。未来应当在以下方面得到进一步的突破:深化黄芪甲苷的机制研究,使其向大样本多中心随机对照的临床研究过渡。确定黄芪甲苷的安全性和有效剂量,从而制定更安全的用药方案。积极探索中药单体之间的协同作用关系。研发与此类相关的多功能复合剂型。把载药系统的优势与其他疗法相结合。对相关的载体系统性进行安全性评价。

Objective: This paper aims to review the regulatory mechanism and carriers of Astragaloside IV (AS-IV) in wound healing cascade related factors, and to provide reference and value basis for the re-development and clinical application of AS-IV intervention in “wound”. Method: “黄芪甲苷”, “Astragaloside IV”, “伤口”, “Wound”, “创面” and “Wound Surface” were selected as search terms through CNKI, VIP, Wanfang and PubMed databases. Results: After removing the literatures with low correlation between AS-IV and the regulatory mechanism and carrier of factors related to wound healing cascade, 43 target literatures were selected. Conclusion: Literature analysis shows that, among the cascade of factors related to wound healing, AS-IV-related mechanism regulation mainly focuses on protecting blood vessels, controlling inflammation, regulating collagen synthesis and conversion, promoting proliferation, migration and differentiation of fibroblasts and epithelial cells, and protecting nerves. The research and development and application of related carriers mainly focus on hydrogels, fibers and biological materials. In the future, further breakthroughs should be made in the following aspects: deepening the mechanism research of astragaloside, so that it can transition to a large sample multi-center randomized controlled clinical study;determining the safe and effective dose of astragaloside to develop a safer medication regimen;actively exploring the synergistic relationship between traditional Chinese medicine monomer;developing multifunctional composite dosage forms related to this category;combining the benefits of drug delivery systems with other therapies;and conducting safety evaluations on relevant carrier systems.